MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Dynamical modulations of low frequency deep brain stimulation on axial symptoms in Parkinson’s disease

    Y. Thenaisie, L. Comeliau, C. Varescon, L. Asboth, M. Castro, J. Bally, G. Courtine, J. Bloch, E. Martin Moraud (Lausanne, Switzerland)

    Objective: First, we aimed to evaluate the optimal contact to address axial symptoms with low frequency deep brain stimulation (LFS). Second, we aimed to evaluate…
  • 2022 International Congress

    Reduced Risk of Mortality and Antipsychotics in Parkinson’s Disease-Related Psychosis: Pimavanserin vs Off-Label Antipsychotics

    S. Isaacson, F. Pagan, D. Truong, V. Abler, R. Pahwa (Boca Raton, USA)

    Objective: Summarize the available data for the mortality risk associated with Parkinson’s disease (PD) psychosis (PDP) and pimavanserin. Background: PDP is associated with increased mortality…
  • 2022 International Congress

    Reported Clinical and Quality-of-Life Outcomes With 24-Hour Levodopa-Carbidopa Intestinal Gel Administration Compared With 16-Hour Administration

    N. Kovács, M. Simu, O. Sanchez Soliño, J. Parra, J. Alcazar, S. Snedecor, V. Fung (Pécs, Hungary)

    Objective: To evaluate any existing differences between the reported outcomes in patients with advanced Parkinson’s disease (APD) using continuous 16-hour (hr) infusions of levodopa-carbidopa intestinal…
  • 2022 International Congress

    Effect of the mGlu2/3 orthosteric agonist LY-404,039 on dyskinesia, psychosis-like behaviours, and parkinsonism in the MPTP-lesioned marmoset

    W. Kang, S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To assess the effect of LY-404,039 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset model of Parkinson’s disease (PD). Background:…
  • 2022 International Congress

    Funding and Sustainability Challenges in Multi-Arm Multi-Stage Clinical Trials in Parkinson Disease

    C. Gonzalez-Robles, J. Ahmed, C. Bale, R. Chapman, S. Clegg, E. Deeson, R. Ellis-Doyle, V. Greaves, J. Handley, E. Henderson, K. Matthews, S. Medd-Phillips, L. Miller, G. Mills, J. Rudiger, ML. Zeissler, C. Carroll, T. Foltynie, S. Gandhi, J. Duffen (London, United Kingdom)

    Objective: The Edmond J Safra Accelerating Clinical Trials in Parkinson Disease (PD) initiative (EJS ACT-PD) aims to accelerate the identification of disease modifying treatment for…
  • 2022 International Congress

    Continuous subcutaneous apomorphine infusion for the management of Parkinson’s disease at the end-of-life

    M. Bereau, M. Giffard, AL. Clairet, M. Verin, M. Auffret (Besançon, France)

    Objective: To describe the benefit of continuous subcutaneous apomorphine infusion (CSAI) for terminal care management in 7 PD patients. Background: There are currently no recommendations…
  • 2022 International Congress

    WATCH-PD: Detecting Early-Stage PD using Feature Engineering and Machine Learning in Remote Sensor-Based Assessments

    D. Anderson, M. Merickel, B. Severson, D. Amato, T. Kangarloo, J. Edgerton, R. Dorsey, J. Adams, S. Jezewski, A. Keil, S. Johnson, M. Kantartjis, S. Polyak, J. Severson, J. Cosman (Horsham, USA)

    Objective: Use feature engineering and machine learning to evaluate digital biomarkers of early-stage Parkinson’s disease (PD) in the WATCH-PD study. Background: WATCH-PD – a one-year…
  • 2022 International Congress

    Early experience using real-world monitoring to inform Parkinson’s management

    W. Chen, L. Kirkby, T. Jansen, G. Philips, T. Haynes, S. Little, J. Jiminez-Shahad, H. Zahed, P. Lin, R. Gilron (San Francisco, USA)

    Objective: To explore the utility of remote patient monitoring, using a combination of brain sensing and objective outcome measurement, in the management of Parkinson’s disease…
  • 2022 International Congress

    Pedunculopontine Nucleus Structural Integrity and Freezing of Gait in Parkinson’s Disease Patients

    K. Yen, R. Camicioli, M. Gee, F. Ba (Edmonton, Canada)

    Objective: We investigated pedunculopontine nucleus (PPN) structural integrity in Parkinson disease (PD) patients with diffusion tensor imaging (DTI) and whether the DTI changes correlate with…
  • 2022 International Congress

    Mechanisms and Consequences of Weight Gain After Deep Brain Stimulation of the Subthalamic Nucleus in Patients with Parkinson’s Disease

    J. Steinhardt, L. Lokowandt, D. Rasche, V. Tronnier, T. Münte, S. Meyhöfer, B. Wilms, N. Brüggemann (Lübeck, Germany)

    Objective: To identify stimulation-dependent effects of deep brain stimulation (DBS) on body weight and energy metabolism depending on the electrode position within the subthalamic nucleus…
  • « Previous Page
  • 1
  • …
  • 239
  • 240
  • 241
  • 242
  • 243
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley